Mario Sznol Clinical Oncology Society of Australia 2014 Annual Scientific Meeting

Abstracts this author is presenting:

• Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-Programmed Death-1) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). — Poster discussion 2